Unlocking the Power of IGF-1

A Deep Dive into Growth, Muscle, and Metabolism

Exploring Insulin-like Growth Factor 1's profound impact on the human body, from cellular regeneration to athletic performance.



Table of content:

Key Insights into IGF-1

- **IGF-1 is a crucial anabolic hormone:** Primarily produced by the liver in response to Growth Hormone (GH), it is vital for muscle growth, tissue repair, and overall development.
- **Balance is paramount:** Both excessively high and extremely low levels of IGF-1 can lead to severe health complications, highlighting the importance of maintaining physiological balance.
  - **Exogenous forms carry significant risks:** While synthetic IGF-1 variants like LR3 and DES are used in bodybuilding for enhanced effects, they bypass natural regulatory mechanisms and are associated with notable health hazards and are prohibited in sports.

Decoding Insulin-like Growth Factor 1 (IGF-1)

Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a polypeptide hormone structurally similar to insulin. It serves as a primary mediator of the anabolic and growth-promoting effects of Growth Hormone (GH). IGF-1 is integral to a complex biological system known as the IGF axis, which includes various receptors, ligands, and binding proteins (IGFBPs) that regulate its activity and availability within the body. Its molecular identity is a 70-amino-acid single-chain peptide encoded by the IGF1 gene on chromosome 12, with different precursor "Ea/Eb/Ec" pro-peptides processed to form mature IGF-1.



A visual representation of the complex molecular structure of Insulin-like Growth Factor 1.

What IGF-1 Accomplishes in the Body

IGF-1 exerts a wide range of biological actions crucial for growth, development, and metabolic regulation. Its primary functions include:

- **Muscle Growth and Hypertrophy:** IGF-1 is a potent anabolic agent that stimulates muscle protein synthesis and inhibits protein breakdown. It plays a critical role in the proliferation and differentiation of satellite cells and myoblasts, which are essential for muscle repair and increasing muscle size (hypertrophy) in response to training. Mechanical loading and muscle contraction actively stimulate IGF-1 production within muscle tissue.
- **Fat Metabolism and Loss:** IGF-1 enhances fat metabolism by increasing the oxidation of fatty acids, helping the body utilize fat stores for energy and contributing to a reduction in body fat.

- **Tissue Repair and Recovery:** It accelerates recovery from intense physical activity and injuries by promoting tissue regeneration, aiding in the repair of damaged cells, and reducing muscle soreness.
- **Bone Development:** IGF-1 stimulates bone growth and density, particularly important during childhood and adolescence, and contributes to bone mineral density in adulthood.
- **Neuroprotection and Nerve Regeneration:** IGF-1 supports brain health, neurogenesis, and synaptic plasticity, potentially offering neuroprotective effects and improving the regenerative characteristics of nerve tissue. It can also upregulate ligament strength.

Physical and Mental Dimensions of IGF-1 Effects

Physical Manifestations

The physical effects of IGF-1 are extensively documented, particularly its profound impact on muscle and body composition. It drives skeletal muscle hypertrophy by enhancing satellite cell activity, which is vital for muscle repair and growth after workouts. This makes it highly sought after in bodybuilding for maximizing muscle mass and strength gains. Furthermore, IGF-1 aids in fat reduction by boosting lipolysis (fat breakdown) and improving insulin sensitivity, fostering a leaner physique. However, excessive levels can lead to adverse physical symptoms such as joint pains, muscle aches, swelling of tissues (edema), and moderate-to-severe hypoglycemia due to its insulin-mimicking properties.

Mental and Cognitive Aspects

While the physical effects are well-established, direct mental effects of IGF-1 are less extensively studied, especially in the context of bodybuilding. Some research suggests IGF-1 supports neurogenesis and synaptic plasticity and is associated with improved mood and cognitive processing. Conversely, imbalances (both excess and deficiency) can manifest as fatigue, brain fog, or anxiety. However, robust data specifically detailing its direct mental benefits or risks in athletes using exogenous forms are limited.

The Origins and Production of IGF-1

IGF-1 is primarily synthesized and secreted by the liver. Hepatocytes within the liver are the major source of circulating IGF-1, accounting for approximately 70-80% of the IGF-1 found in the bloodstream. This production is predominantly stimulated by Growth Hormone (GH), released from the pituitary gland. GH binds to specific receptors on liver cells, triggering a cascade that culminates in IGF-1 synthesis and secretion.

Beyond the liver, IGF-1 is also produced in smaller quantities by various other tissues, including skeletal muscle, bone, and cartilage. In these tissues, it often acts locally in an autocrine (on the same cell) or paracrine (on nearby cells) manner, contributing to localized growth and repair processes, particularly during exercise or injury. However, this local production does not significantly contribute to overall circulating IGF-1 levels.

Stimulating IGF-1 Secretion and Influencing Factors

Several factors can naturally increase IGF-1 secretion:

- **Exercise:** Resistance training and high-intensity exercise are powerful physiological stimulators of GH release, which in turn elevates IGF-1 production. Mechanical loading and muscle contraction acutely raise IGF-1 levels post-workout. **Sleep:**
- Deep sleep stages (NREM) are critical for pulsatile GH secretion, which subsequently boosts IGF-1 levels. Poor sleep can depress these levels.
- **Nutrition:** Adequate intake of high-quality protein is essential, as IGF-1 is involved in protein synthesis. Sufficient energy intake, along with nutrients like zinc, selenium, and vitamin D, also supports optimal IGF-1 levels. Avoiding chronic very-low-carb or fasting regimens during hypertrophy phases can also help maintain IGF-1 by moderating IGFBP-1 and favoring free IGF-1.
- **Growth Hormone (GH) Secretagogues:** Compounds that stimulate endogenous GH release can indirectly increase IGF-1.

Conversely, several factors can negatively impact IGF-1 secretion:

- **Age:** IGF-1 levels naturally increase during childhood, peak at puberty, and then steadily decline with age, mirroring GH secretion patterns.
- **Nutritional Status:** Malnutrition, severe caloric restriction, or chronic fasting can significantly lower IGF-1 levels.
- **Liver Health:** Conditions like chronic liver disease, cirrhosis, or non-alcoholic fatty liver disease (NAFLD) can impair the liver's ability to produce IGF-1, leading to reduced circulating levels.
- **Stress:** Chronic stress and elevated cortisol levels can suppress GH receptor signaling, thereby reducing IGF-1 production.
- **Medical Conditions:** Conditions such as GH deficiency, insulin resistance, or chronic inflammation can disrupt the GH-IGF-1 axis. Elevated IGFBP-1/2 can also lower bioavailable IGF-1.

The Dual Edge of IGF-1: Benefits and Risks

Advantages of Optimal IGF-1 Levels

Under normal physiological conditions, sufficient IGF-1 levels are crucial for numerous bodily functions. For bodybuilders and athletes, high-normal levels (typically 250–350 µg/L in adults) offer several perceived and actual benefits:

- **Enhanced Muscle Growth:** Significant muscle hypertrophy and strength gains through increased protein synthesis and satellite cell activation.
- **Accelerated Recovery:** Faster recovery from intense workouts and injuries due to enhanced tissue repair and reduced delayed onset muscle soreness (DOMS).
- **Improved Body Composition:** Better fat metabolism and weight management through increased lipid oxidation.
- **Bone and Joint Health:** Increased bone mineral density and greater collagen synthesis, contributing to stronger bones and improved joint recovery.
- **Potential Mood Elevation:** While not extensively studied in athletes, optimal IGF-1 levels are associated with improved mood and cognitive processing.

Perils of Excessively High IGF-1 Levels

Chronic supra-physiological levels of IGF-1 (often exceeding 600 µg/L due to abuse of exogenous forms) pose significant health risks:

- **Metabolic Disturbances:** Moderate-to-severe hypoglycemia due to its insulin-like properties, and paradoxically, long-term insulin resistance and increased risk of type 2 diabetes.
- **Abnormal Tissue and Organ Growth:** IGF-1 affects all tissues. Excessive use can lead to acromegaly-like symptoms, including enlarged hands, feet, and facial features. It

can also cause visceral organomegaly (enlargement of internal organs), particularly the tongue, intestines (leading to "GH gut" or "bubble gut"), heart, liver, and kidneys.
- **Increased Cancer Risk:** Elevated IGF-1 levels have been linked to an increased predisposition to certain cancers, including prostate, colorectal, and hepatic cancers, as it promotes cell proliferation.
- **Other Side Effects:** Edema (fluid retention), carpal tunnel syndrome, accelerated acne, joint and muscle pains, headaches, nausea, erythema, and lipohypertrophy at injection sites. Long-term abuse can also lead to down-regulation of endogenous GH and IGF1R desensitization.



This bar chart illustrates the perceived benefits of healthy IGF-1 levels versus the severe risks associated with excessively high levels, particularly from exogenous use. It highlights that while optimal IGF-1 promotes desirable physiological outcomes, super-physiological levels can lead to significant and detrimental side effects, especially those related to abnormal growth and metabolic dysfunction.

Consequences of Insufficient IGF-1 Levels

Persistently low IGF-1 levels (below 70 µg/L in adults) can indicate Growth Hormone Deficiency (GHD) or insensitivity to GH, leading to various health issues:

- **Growth Retardation:** In children, low IGF-1 can result in stunted growth, short stature, and delayed puberty.
- **Muscle Wasting and Sarcopenia:** In adults, low levels are associated with impaired muscle protein synthesis, reduced muscle mass (sarcopenia), and decreased strength.
- **Bone Weakness:** Reduced bone density and an increased risk of osteoporosis and fractures.
- **Fatigue and Weakness:** General feelings of fatigue, decreased energy, and overall weakness.
- **Metabolic and Cardiovascular Issues:** Can lead to altered lipid profiles (e.g., high LDL) and impaired endothelial function.
- **Mood and Cognitive Impairment:** Reduced mood, energy, and cognitive function ("brain fog").

The Liver's Pivotal Role in IGF-1 Production

The liver is the principal organ responsible for the synthesis and secretion of circulating IGF1, producing approximately 75% of the body's total IGF-1. This process is primarily initiated by Growth Hormone (GH) stimulation. Hepatocytes, the main liver cells, express GH receptors. When GH binds to these receptors, it activates signaling pathways that trigger the production and release of IGF-1, as well as IGF-binding proteins (IGFBPs) and the acidlabile subunit (ALS), which together transport IGF-1 in the blood and extend its half-life.

The liver-derived IGF-1 plays a critical, non-redundant role in regulating numerous physiological parameters beyond bone growth, including GH secretion (via negative feedback), cortical bone mass, kidney and prostate size, peripheral vascular resistance, spatial memory, sodium retention, insulin sensitivity, and liver size. Consequently, liver dysfunction, such as chronic liver disease, cirrhosis, or liver failure, can significantly reduce IGF-1 levels, directly correlating with the severity of hepatic impairment and leading to associated systemic health issues.



A diagram illustrating the intricate relationship between Growth Hormone (GH), the liver, and IGF-1 production, highlighting the central role of the liver in this endocrine axis.

Endogenous vs. Exogenous IGF-1: A Critical Comparison

The distinction between naturally produced (endogenous) and externally administered (exogenous) IGF-1 is crucial, especially in performance-enhancing contexts:

Feature	Endogenous IGF-1	Exogenous IGF-1

Origin	Naturally produced, primarily by the liver in response to GH.	Administered synthetically (e.g., IGF-1 LR3, IGF-1 DES).
Regulation	Tightly regulated by the GH/IGF-1 axis, negative feedback loops, and IGFBPs.	Bypasses natural regulatory mechanisms, leading to prolonged and amplified effects.
Half-life	Relatively short (12-15 minutes in unbound form, hours when bound to IGFBPs).	Modified forms have significantly extended half-lives (e.g., LR3: 20-30 hours).
Binding	>95% bound to IGFBPs, forming a ternary complex that regulates bioavailability.	Modified forms (e.g., LR3) have significantly reduced IGFBP affinity, increasing free fraction.
Systemic vs. Local	Both systemic (endocrine) from liver and local (autocrine/paracrine) from tissues.	Systemic for LR3; localized for DES if siteinjected.
Risks	Naturally regulated; risks primarily from deficiency or disease.	High risk of severe side effects (hypoglycemia, organomegaly, cancer risk) due to supraphysiological levels and lack of natural regulation. Prohibited in sports.

This table provides a comprehensive comparison between endogenous (naturally produced) and exogenous (externally administered) IGF-1, highlighting their distinct characteristics, regulatory mechanisms, and associated risks.

Differentiating IGF-1 LR3, IGF-1 DES, and Increlex

Within the realm of exogenous IGF-1, several variants exist with distinct properties:

- **IGF-1 LR3 (Long R3 IGF-1):** This is a synthetic analog of IGF-1 not naturally found in the human body. It features a 13-residue N-terminal extension and an arginine-toglutamic acid substitution. These modifications significantly reduce its affinity for IGF-binding proteins (IGFBPs) to about 1% of native IGF-1, resulting in a much longer half-life of 20-30 hours. IGF-1 LR3 is considered more potent than basic IGF-1 and acts more systemically, making it popular among bodybuilders for sustained muscle growth, fat loss, and recovery. However, prolonged use can lead to receptor desensitization. Typical protocols involve daily intramuscular (IM) or subcutaneous (sub-Q) injections of 20-60 µg for 4-6 weeks.
- **IGF-1 DES (Des(1-3)-IGF-1):** This variant is a naturally occurring, truncated form of IGF-1, missing the first three N-terminal amino acid residues. It boasts a 10-fold greater receptor affinity than native IGF-1 but has a much shorter half-life of approximately 20-30 minutes. IGF-1 DES is highly potent locally and is often used for site-specific injections into target muscle groups, particularly immediately preworkout. It is known to bind effectively to receptors deformed by lactic acid, allowing it to signal tissue growth even during intense training. DES can often be used more frequently and for longer durations than LR3. Dosing typically involves 20-40 µg intramuscularly into the target muscle pre-training.
- **Increlex (Mecasermin):** This is a pharmaceutical-grade, recombinant human IGF-1 that is identical to the native 70-amino-acid sequence. Increlex is medically approved for the treatment of severe primary IGF-1 deficiency in children. It is not typically used for bodybuilding purposes and is administered under strict pediatric endocrinology control. Its half-life is approximately 6 hours when co-administered with IGFBP-3 (as mecasermin rinfabate).

The Intricate Correlation Between Growth Hormone and IGF-1 Levels

Growth Hormone (GH) and IGF-1 are inextricably linked through the GH/IGF-1 axis, a critical endocrine pathway regulating growth and metabolism. GH, primarily secreted in pulsatile bursts by the pituitary gland, acts as the upstream regulator. Upon release, GH travels to the liver, where it binds to specific GH receptors on hepatocytes. This binding stimulates the liver to synthesize and secrete IGF-1 into the bloodstream. IGF-1 then mediates many of the anabolic and growth-promoting effects attributed to GH, such as muscle hypertrophy, fat loss, and tissue repair.

This relationship also involves a crucial negative feedback loop: elevated IGF-1 levels signal back to the pituitary gland and hypothalamus, inhibiting further GH secretion. This regulatory mechanism helps maintain homeostatic balance in the body's growth processes. Consequently, IGF-1 levels often serve as a stable and reliable indicator of average GH secretion over time, making it a valuable diagnostic marker for GH excesses or deficiencies.

This mindmap illustrates the intricate relationship within the GH/IGF-1 axis, depicting how Growth Hormone from the pituitary stimulates IGF-1 production in the liver, which then mediates growth effects and provides negative feedback to regulate GH secretion.

Conversion of Exogenous Growth Hormone to IGF-1

When exogenous human growth hormone (HGH) is administered, it directly stimulates the liver to produce and release IGF-1, mimicking the body's natural physiological pathway. While HGH itself does not directly cause muscle growth, it facilitates it by signaling the release of IGF-1. The precise quantitative conversion rate from exogenous GH to IGF-1 can vary significantly based on individual factors such as liver health, GH dosage, duration of administration, and individual response to the hormone. For instance, each 1 IU (approximately 0.33 mg) of exogenous recombinant human GH (rhGH) administered subcutaneously can raise mean 24-hour serum IGF-1 by approximately 25–40 µg/L after reaching steady state. Bodybuilders often use higher doses (e.g., 3-8 mg/day or 4-8 IU/day) in cycles to maximize this conversion and leverage its anabolic effects, driving IGF-1 levels to supraphysiological ranges (500–900 µg/L). However, beyond a certain point, the efficiency of this conversion plateaus as hepatic GH receptors become saturated, meaning additional GH yields diminishing IGF-1 increments but potentially more side effects like water retention and insulin resistance.

Strategic Comparisons: Exogenous IGF-1 vs. Exogenous Growth Hormone

For individuals seeking enhanced muscle growth and performance, particularly in bodybuilding, the choice between exogenous IGF-1 and exogenous GH (or a combination) involves distinct pharmacological profiles, benefits, and risks:



This radar chart compares the attributes of using exogenous IGF-1 directly versus relying on IGF-1 produced from exogenous Growth Hormone, based on a scale of 0 to 5. It highlights the directness and speed of IGF-1 administration against the more systemic and potentially less immediate effects of GH, while also assessing relative risks.

1. Taking Exogenous IGF-1 Alone:

- **Pros:** Directly introduces IGF-1, leading to immediate receptor activation and rapid anabolic effects on muscle growth and fat loss. Variants like IGF-1 DES allow for sitespecific hypertrophy and can be less associated with GH-mediated fluid retention. LR3 provides sustained systemic effects due to its long half-life and reduced IGFBP binding, leading to a higher free fraction.
- **Cons:** Bypasses the body's natural GH production and its intricate regulatory mechanisms, potentially leading to rapid receptor down-regulation and profound hypoglycemia risk (requiring careful peri-injection carbohydrate management). It carries a higher risk of systemic side effects like organomegaly due to unregulated systemic exposure. Evidence also suggests that increasing circulating IGF-1 experimentally in healthy individuals might have negligible effects on muscle protein synthesis or strength augmentation compared to natural mechanisms. Furthermore, all exogenous IGF-1 forms and analogs are on WADA's Prohibited List, making them detectable in doping controls.

2. Taking Exogenous Growth Hormone (GH) Alone and Relying onEndogenous IGF-1 Production:

- **Pros:** This method leverages the body's natural physiological pathway, where GH stimulates endogenous IGF-1 production in the liver. It's often considered a safer approach for increasing IGF-1 levels, as the conversion is mediated by the body's own

regulatory systems (though supraphysiological GH doses will still overwhelm these). GH also stimulates both endocrine IGF-1 and local muscle IGF-1 isoforms, and it has distinct lipolytic (fat-burning) effects. Pharmaceutical quality control for rhGH is generally easier.

- **Cons:** The onset of IGF-1 benefits is slower (days) as it depends on liver conversion. It requires an intact and healthy liver to produce IGF-1 effectively. High doses can still lead to fluid retention, insulin resistance, and the cumulative risks of GH abuse, such as acromegaly and non-reversible side effects to the heart, joints, and liver. Studies do not always support that GH doping significantly enhances performance or muscle mass gains in healthy individuals beyond concurrent anabolic steroid use. GH also raises IGFBP-3, which can sequester IGF-1, potentially reducing its immediate free fraction.

3. Combining Exogenous GH and Exogenous IGF-1:

- **Rationale:** This strategy aims to maximize anabolic effects by providing both the upstream stimulus (GH) and the direct effector (IGF-1). The GH component might counter IGF-1-induced feedback suppression of GH, maintain lipolysis, and support night-time recovery.
- **Risks:** The risks of each compound are amplified. This combination significantly increases the likelihood and severity of adverse effects, including profound insulin resistance, organ growth (including "GH gut"), and severe hypoglycemia. The cost of such a regimen is also substantially higher than single-compound use. Most experienced coaches reserve combined use for plateau phases in elite preparation and limit the duration to very short cycles (e.g., ≤4–6 weeks) due to the cumulative risks and rapid tolerance development.

In conclusion, while both exogenous IGF-1 and exogenous GH (which increases IGF-1) are utilized for anabolic purposes, particularly in bodybuilding, they both carry significant health risks and are strictly prohibited in professional sports. The body's natural regulatory systems are highly complex, and introducing exogenous hormones disrupts this delicate balance, leading to unintended and potentially harmful long-term consequences. For most athletes, optimizing endogenous IGF-1 through natural means (training, diet, sleep) remains the most prudent and safe strategy.

Conclusion

Insulin-like Growth Factor 1 (IGF-1) stands as a potent anabolic hormone, intrinsically linked to Growth Hormone and central to processes of growth, development, and tissue repair. Its profound effects on muscle hypertrophy, fat metabolism, and recovery make it a subject of considerable interest, particularly in the realm of bodybuilding. However, the delicate balance of IGF-1 levels is critical for health. While optimizing endogenous IGF-1 through natural means—such as consistent resistance training, adequate nutrition, and sufficient sleep—offers substantial benefits for muscle growth and overall well-being, the allure of exogenous IGF-1 variants like LR3 and DES comes with significant caveats. These synthetic forms, though powerful, disrupt the body's natural regulatory mechanisms, leading to a heightened risk of severe side effects, including metabolic disturbances, abnormal organ growth, and increased cancer predisposition. The scientific consensus underscores that the pursuit of supraphysiological IGF-1 levels through artificial means carries disproportionate risks to long-term health and is prohibited in competitive sports. Ultimately, for sustainable and safe physiological enhancements, nurturing the body's intrinsic GH-IGF-1 axis through mindful lifestyle choices remains the most prudent and effective strategy.

References

en.wikipedia.org

Insulin-like growth factor 1 - Wikipedia

pnas.org

Liver-derived insulin-like growth factor I (IGF-I) is the ... - PNAS

usada.org

IGF-1 and the World Anti-Doping Agency Prohibited List | USADA

mdpi.com

The Role of Insulin-like Growth Factor-1 (IGF-1) in the Control of ... - MDPI

physoc.org

The mighty protein: insulin-like growth factor type 1 - The Physiological Society

joe.bioscientifica.com

IGF1 stimulates greater muscle hypertrophy in the absence of ... Journal of Endocrinology

frontiersin.org

The Role of the IGF-1 Signaling Cascade in Muscle Protein ... Frontiers in Nutrition

jme.bioscientifica.com

Understanding the tissue-specific roles of IGF1/IGF1R in regulating ...

sciencedirect.com

The signaling landscape of insulin-like growth factor 1 - ScienceDirect

sciencedirect.com

IGF-1 contributes to liver cancer development in diabetes patients by ...

onlinelibrary.wiley.com

Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: A preliminary prospective study

pmc.ncbi.nlm.nih.gov

Insulin-like growth factor in muscle growth and its potential abuse by athletes - PMC

pmc.ncbi.nlm.nih.gov

Insulin-Like Growth Factor-1 Physiology: Lessons from Mouse Models

musculation-bodybuilding.com

IGF-1 LR3 Review - Dosage, effets secondaires, dangers, piles

e-enm.org

The Fascinating Interplay between Growth Hormone, Insulin-Like ...

translational-medicine.biomedcentral.com

Human conditions of insulin-like growth factor-I (IGF-I) deficiency ...

pubmed.ncbi.nlm.nih.gov

The role of liver-derived insulin-like growth factor-I - PubMed

onlinelibrary.wiley.com

Insulin-like growth factor-1 is inversely associated with liver fibrotic ...

mdpi.com

Insulin-Like Growth Factor (IGF) System in Liver Diseases

zenodo.org

IGF-1 Therapy in Children with Liver Dysfunction

en.wikipedia.org

Insulin-like growth factor - Wikipedia

dietvsdisease.org

IGF-1: Miracle Hormone or Health Hazard? | Diet vs Disease

onlinelibrary.wiley.com

Effects of IGF-1 isoforms on muscle growth and sarcopenia - Ascenzi - 2019 - Aging Cell - Wiley Online Library

ncbi.nlm.nih.gov

Insulin-like growth factor 1 (IGF-1): a growth hormone - PMC uk-

vivo.colostate.edu

insulin-like growth factor-I (IGF-I)

healthline.com

Peptides for Bodybuilding: Do They Work, and Are They Safe?

ncbi.nlm.nih.gov

Insulin-like Growth Factors in the Gastrointestinal Tract and Liver

pubmed.ncbi.nlm.nih.gov

Detection of LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I using ...

pnas.org

Attenuation of insulin secretion by insulin-like growth factor 1 ... - PNAS

onlinelibrary.wiley.com

Insulin-like growth factor-I and the liver

pmc.ncbi.nlm.nih.gov

The Role of Liver-Derived Insulin-Like Growth Factor-I

academic.oup.com

Growth Hormone and Insulin-Like Growth Factor 1 Regulation of ...

pmc.ncbi.nlm.nih.gov

Insulin-Like Growth Factor (IGF) System in Liver Diseases - PMC

sciencedirect.com

Insulin-Like Growth Factor - an overview | ScienceDirect Topics

bpspubs.onlinelibrary.wiley.com

Regulation of muscle mass by growth hormone and IGF-I - Velloso 2008 - British Journal of Pharmacology - Wiley Online Library

karger.com

Metabolic Functions of Liver-Derived (Endocrine) Insulin-Like Growth Factor I

sciencedirect.com

Insulin-like growth factor-1 and resistance exercise in community dwelling old adults - ScienceDirect

karger.com

Possible Roles of Insulin-Like Growth Factor in Regulation of Physiological and Pathophysiological Liver Growth

evolutionary.org

Insulin-like growth factor-1 (IGF-1) - Evolutionary.org

pmc.ncbi.nlm.nih.gov

Use of Growth Hormone, IGF-I, and Insulin for Anabolic Purpose: Pharmacological Basis, Methods of Detection, and Adverse Effects - PMC